18 / 46
Pain Management 2019 & Internal Medicine 2019
International Journal of Anesthesiology & Pain Medicine
ISSN: 2471-982X
Page 56
JOINT EVENT
7
th
Edition of International Conference on
Pain Management
8
th
Edition of International Conference on
Internal Medicine &
Patient Care
&
March 25-26, 2019
Rome, Italy
Int J Anesth Pain Med 2019, Volume 5
DOI: 10.21767/2471-982X-C1-006
Anti VEGFR therapy for osteoarthritis pain
Hee-Jeong Im Sampen
Jesse Brown Veterans Affairs Medical Center (JBVAMC) - University
of Illinois at Chicago, USA
O
steoarthritis (OA), referred as arthritis, is among the
most common chronic conditions among adults.
Osteoarthritic symptom, pain, is the key reason to seek
medical assistance, yet there is no effectiveway to relieve
OA-induced pain. Despite the major negative impact that
severe pain in chronic OA has on quality of life and health
care management, we only poorly understand origins
of pain in OA, the molecular mechanisms driving the
pathology, and theway to effectively cureOA. Many cases
eventually require joint replacement with a prosthesis
whichiscostly,andthelimitedfunctionallifeofprostheses
(~10 y) can make a second replacement necessary.
These factors increase both the overall cost of treatment
and the risk for associated morbidity. Significantly,
surgical procedures to address the condition typically do
not result in a pain-free cure. The central aim of our sutdy
is to test that the activation of Flt1 (vascular endothelial
growth factor receptor-1) is the major driver of joint pain
transmission by plasticity of peripheral (sensory neurons)
and central glial activation; Flk1 (vascular endothelial
growth factor receptor-2) is primarily responsible for
cartilage degeneration during the OA progression, thus,
simultaneous inhibition of Flt1 and Flk1 by pazopanib, an
FDA-approved small molecule anti-cancer drug, will act
as an ideal OA disease-modifying drug (OADMD) with
immediate reduction of joint pain and gradually cartilage
regeneration. The findings of our proposed research will
take the field of OA research a giant step forward: in the
short term, by increasing our mechanistic understanding
of the causes and progression of OA, and by developing
a novel strategy for treating OA and joint pain effectively
and safely in our pre-clinical OA animal model; and, in the
longer term, by providing a rationale for clinical trials to
test pazopanib to treat OA patients.
imsampen007@gmail.com